Global /Sweden /Healthcare /Biotechnology /KDEV

KDventures AB

KDEV

• STO: KDEV • Delayed

0.2800SEK -3.4%

0.0299 USD

As of 5 June 2026, KDventures AB has a market cap of $19.62M USD, ranking #37238 globally and #553 in Sweden. It ranks #3339 in the Healthcare sector, and #658 in the Biotechnology industry.

Global Rank

37238

Country Rank

553

Sector Rank

3339

Industry Rank

658

Key Stats

Market Cap

$19.62MUSD

184.6M SEK

Enterprise Value

$17.26MUSD

161.8M SEK

Revenue (TTM)

$177.64KUSD

1.67M SEK

EBITDA (TTM)

-$2.12MUSD

-19.89M SEK

Net Income (TTM)

-$20.61MUSD

-193.86M SEK

PS Ratio

110.5

PB Ratio

0.2

Company Profile

Country (HQ)

Sweden

Sector

Healthcare

Industry

Biotechnology

CEO

Viktor Drvota open_in_new

Employees

Founded

2003

Website

karolinskadevelopment.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.4%	8.3%	11%	-1.8%	-68%	-36%	-70%	-83%	-82%

News

Markets

Exchange	Ticker	Price	Quotes
Nasdaq Stockholm (STO) MIC: XSTO PRIMARY	KDEV Karolinska Development AB Class B ISIN: SE0002190926 Shares Out.: Shares Outstanding: 935.473M¹ Shares Float: 372.593M² TV: TradingView: OMXSTO: KDEV SA: Stock Analysis: STO: KDEV YF: Yahoo Finance: KDEV.ST GF: Google Finance: STO: KDEV BA: Barron's: KDEV MS: Morningstar: XSTO: KDEV	0.2800 SEK	TV: TradingView: OMXSTO: KDEV SA: Stock Analysis: STO: KDEV YF: Yahoo Finance: KDEV.ST GF: Google Finance: STO: KDEV BA: Barron's: KDEV MS: Morningstar: XSTO: KDEV
London Stock Exchange (LSE / LON) MIC: XLON	0P3C Karolinska Development AB Class B ISIN: SE0002190926 Shares Out.: Shares Outstanding: 656.729M¹ Shares Float: 261.571M² TV: TradingView: LSE: 0P3C SA: Stock Analysis: LON: 0P3C YF: Yahoo Finance: 0P3C.L GF: Google Finance: LON: 0P3C BA: Barron's: 0P3C MS: Morningstar: XLON: 0P3C	0.3105 SEK	TV: TradingView: LSE: 0P3C SA: Stock Analysis: LON: 0P3C YF: Yahoo Finance: 0P3C.L GF: Google Finance: LON: 0P3C BA: Barron's: 0P3C MS: Morningstar: XLON: 0P3C

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About KDventures AB

KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. The company was formerly known as Karolinska Development AB (publ) and change its name to KDventures AB in February 2026. KDventures AB was founded in 2003 and is headquartered in Solna, Sweden.

Similar Companies

Industry: Biotechnology (Sweden)

Name	Market Cap (USD) diff.	PE	Country
Vimian Group AB (publ) STO: VIMIAN	$1.58B 14.9B SEK 8K%	43.7	Sweden
BioInvent International AB (publ) STO: BINV	$150.75M 1.42B SEK 668%	-	Sweden
BICO Group AB (publ) STO: BICO	$141.2M 1.33B SEK 620%	-	Sweden
Cinclus Pharma Holding AB (publ) STO: CINPHA	$60.16M 565.9M SEK 207%	-	Sweden
Intervacc AB (publ) STO: IVACC	$41.67M 391.94M SEK 112%	-	Sweden
Bio-Works Technologies AB (publ) NGM: BIOWKS	$32.98M 310.2M SEK 68%	-	Sweden

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 929K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 815K%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 245K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.48B 68.19T KRW 227K%	35.5	South Korea
CSL Ltd. ASX: CSL	$43.01B 60.27B AUD 219K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 217K%	37.2	Switzerland

chevron_leftBack